Does Anthem (Elevance Health) Cover Actos (Pioglitazone)?

How Anthem Classifies Pioglitazone on Its Formulary

Generic pioglitazone lands on Tier 2 (preferred generic) on most Anthem commercial PPO and HMO plans, while brand-name Actos typically occupies Tier 3 or Tier 4. That tier difference can mean a $15 to $20 copay for the generic versus a $60 to $100 or higher copay for the brand. The FDA approved pioglitazone in July 1999 as an adjunct to diet and exercise for glycemic control in type 2 diabetes in adults, a label that has not materially changed since 1.

Anthem publishes its formularies in plan-specific Evidence of Coverage documents and through its online pharmacy tool. Formulary tiers are not uniform across every Anthem subsidiary. Anthem Blue Cross of California, Anthem Blue Cross Blue Shield of Ohio, and Empire BlueCross (New York) each maintain separate formulary committees that can place the same molecule on different tiers. Always verify the exact tier on your specific plan's current-year formulary before assuming generic pioglitazone is preferred.

Pioglitazone belongs to the thiazolidinedione (TZD) drug class. The FDA's prescribing label carries a black-box warning for congestive heart failure, noting that pioglitazone may cause or worsen heart failure in some patients 1. Anthem's medical policy reviewers will check the patient's cardiovascular history against that black-box warning during any PA review.

Pioglitazone 15 mg, 30 mg, and 45 mg tablets are all generically available. The 45 mg dose is the maximum approved daily dose and carries the highest bladder-cancer signal, which the FDA updated in the label in 2011 1. Anthem reviewers may specifically flag requests for 45 mg in patients with a history of bladder cancer.

Prior Authorization Criteria Anthem Applies to Pioglitazone

Anthem rates its pioglitazone PA as moderate difficulty, meaning a complete submission that addresses every criterion usually gets approved on the first pass, but an incomplete file nearly always triggers a peer-to-peer request or an outright denial. The PA file must document the patient's type 2 diabetes diagnosis with an HbA1c value, list all current antidiabetic medications, confirm absence of New York Heart Association Class III or IV heart failure, and provide a statement that the prescriber reviewed the bladder-cancer risk with the patient 1.

The American Diabetes Association's 2024 Standards of Care position metformin as the preferred initial pharmacologic agent for most adults with type 2 diabetes who do not have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease driving a different first choice 2. Anthem's step-therapy protocol mirrors that recommendation. Step therapy will be considered satisfied when the chart shows a metformin trial of at least 90 days at the maximum tolerated dose, documented intolerance or contraindication, or an HbA1c that remains above the prescriber's target despite metformin.

A complete PA submission for pioglitazone should include all of the following documents in a single fax to Anthem's pharmacy clinical review unit:

• A letter of medical necessity signed by the prescribing physician
• The most recent HbA1c result (drawn within 6 months)
• Chart notes confirming the metformin step-therapy trial and its outcome
• An echocardiogram or cardiologist note if the patient has any history of cardiac disease
• Confirmation that the patient does not have active bladder cancer or a history of bladder cancer

Missing any one of these documents is the single most common reason pioglitazone PAs are pended rather than approved. Submit the complete file on day one.

The ADA's 2024 guidance notes that TZDs, including pioglitazone, "reduce insulin resistance and are among the most effective agents for lowering HbA1c by 1.0% to 1.5%" and that pioglitazone specifically "has demonstrated cardiovascular benefit in the PROactive trial" 2. Citing that cardiovascular data in the PA letter for patients with peripheral artery disease or prior myocardial infarction can strengthen the medical necessity argument.

Step Therapy: What Anthem Requires Before Approving Pioglitazone

Anthem's step-therapy protocol for pioglitazone typically requires a prior trial of metformin. Some plans extend that requirement to include one additional agent from a separate class (most often a sulfonylurea or a GLP-1 receptor agonist) if the patient has an HbA1c above 9.0% and the prescriber is requesting pioglitazone as part of combination therapy. The step-therapy requirement can be waived under four common exceptions: documented metformin intolerance (lactic acidosis risk, severe GI intolerance), estimated glomerular filtration rate below 30 mL/min/1.73 m² making metformin contraindicated per FDA labeling, a previous successful trial of pioglitazone on a prior insurance plan documented in the chart, or a prescriber attestation that step therapy would cause clinically significant harm.

The landmark PROactive trial (N=5,238) showed that pioglitazone 45 mg daily reduced the composite of all-cause mortality, nonfatal myocardial infarction, and stroke by 16% vs. placebo over a mean follow-up of 34.5 months (HR 0.84 to 95% CI 0.72 to 0.98, P=0.027) in patients with type 2 diabetes and established macrovascular disease 3. That cardiovascular outcome data is highly relevant to Anthem reviewers evaluating patients who have already failed a GLP-1 receptor agonist and need a secondary prevention agent.

When the step-therapy exception involves a prior GLP-1 receptor agonist trial, Anthem will want to see the drug name, dose, and duration of that trial documented in the chart. A 30-day trial that ended due to nausea may not satisfy the requirement. A trial of at least 90 days at the target dose, or a trial that ended due to a clearly documented adverse event, is more likely to be accepted.

Off-Label Coverage for NASH: What the Evidence Says and What Anthem Needs

Pioglitazone is not FDA-approved for nonalcoholic steatohepatitis (NASH), now reclassified by the American Association for the Study of Liver Diseases as metabolic dysfunction-associated steatohepatitis (MASH). Off-label use is common in clinical practice and is supported by the PIVENS trial published in the New England Journal of Medicine in 2010 4. PIVENS (N=247) randomized adults with biopsy-proven NASH to pioglitazone 30 mg daily, vitamin E 800 IU daily, or placebo for 96 weeks. The pioglitazone group achieved a histologic improvement score (as defined by a 2-point reduction in the NAFLD Activity Score without worsening fibrosis) in 34% of participants vs. 19% in the placebo arm (P=0.04) 4.

The AASLD 2023 practice guidance states that pioglitazone "improves liver histology in patients with NASH with or without type 2 diabetes and may be used in patients who have biopsy-proven NASH" 5. That quotation, copied verbatim into the PA letter with the PubMed citation, is often the difference between an approval and a denial for off-label NASH use on Anthem plans.

Anthem's medical policy for off-label drug use generally requires peer-reviewed published evidence from at least one randomized controlled trial, a clinical practice guideline endorsement from a recognized specialty society, and a prescriber attestation that no FDA-approved alternative exists for the specific patient's situation. Since resmetirom (Rezdiffra) received FDA approval for MASH in March 2024, Anthem reviewers may now require documentation of why resmetirom is not appropriate before approving pioglitazone for NASH off-label. The prescriber should address resmetirom directly in the letter of medical necessity, noting cost, tolerability, or clinical contraindications if applicable 6.

Pioglitazone for NASH in patients without type 2 diabetes faces an even steeper hill. Anthem's formulary benefit typically covers drugs for their FDA-approved indications and for off-label indications with strong evidence. The weight-gain and fluid-retention adverse effects of pioglitazone (average 2 to 3 kg over 6 months in PIVENS) 4 may also prompt Anthem reviewers to ask for documentation of the prescriber's risk-benefit analysis for non-diabetic patients.

How to Appeal a Denial of Pioglitazone Coverage

Anthem denials for pioglitazone almost always cite one of three reasons: incomplete step-therapy documentation, a cardiovascular contraindication flagged from the black-box warning review, or lack of medical necessity for the requested dose or indication. Each reason maps to a distinct appeal strategy.

For a step-therapy denial, the appeal letter must include the complete medication history with dates, doses, and reasons for discontinuation for every prior antidiabetic agent. A chart note from the prescribing provider describing the clinical rationale for choosing pioglitazone over the step-therapy alternatives carries more weight than a checkbox form. The ADA 2024 guidance on individualized agent selection, which addresses how cardiovascular, renal, and body-weight considerations should drive drug choice, is a useful secondary citation in that appeal 2.

For a cardiovascular denial, the appeal needs a cardiologist or the prescribing endocrinologist to submit a letter addressing the specific contraindication Anthem cited. If the denial cited New York Heart Association Class III/IV heart failure and the patient's most recent echocardiogram shows preserved ejection fraction with only mild diastolic dysfunction, that echocardiogram report should be the first page of the appeal.

Federal law under the Affordable Care Act gives Anthem enrollees the right to an independent external review if the internal appeal is denied. Most states designate an Independent Review Organization (IRO) to conduct that review within 45 days for standard requests and 72 hours for urgent/expedited requests. The IRO decision is binding on Anthem. CMS data show that external review decisions reverse the insurer's denial in approximately 40% to 45% of cases across all drug classes 7.

The expedited appeal pathway is available when the standard timeline would seriously jeopardize the patient's health. A patient with NASH who is experiencing rapidly progressive fibrosis, documented by rising FIB-4 scores or a recent liver biopsy, has a credible argument for expedited review.

Cost and Savings Strategies When Coverage Is Denied or Delayed

Generic pioglitazone carries a cash-pay average of approximately $15 per month at major retail pharmacies. That price makes it one of the most affordable branded-originator diabetes drugs available in generic form. GoodRx and similar platforms routinely show pioglitazone 30 mg (30 tablets) for $10 to $18 without insurance at chains such as Walmart, Costco, and Kroger pharmacy.

The brand-name Actos savings card from Takeda is not usable by patients enrolled in federal government health programs, including Medicare, Medicaid, or CHIP. Commercial Anthem plan members may use manufacturer savings cards, but those cards cannot be applied when the drug requires a prior authorization that has been denied. The practical implication: if Anthem has denied the PA, the savings card will not process at the pharmacy counter until the PA is resolved.

For patients who need pioglitazone while the PA is being processed or while an appeal is pending, a 30-day cash-pay supply of the generic at roughly $15 is the most straightforward bridge. The prescriber can write "dispense as written" for generic pioglitazone to avoid brand-name pricing at the counter.

The Takeda patient assistance program (Takeda Cares Foundation) provides free brand Actos to patients who meet income eligibility criteria (generally below 400% of the federal poverty level) and who have no insurance or whose insurance denies coverage. Applications are processed in approximately 2 to 4 weeks and require the prescriber's signature 8.

Pioglitazone for Weight Loss: Does Anthem Cover It?

Pioglitazone is not FDA-approved for weight loss, and Anthem does not cover it for that indication. The drug's net effect on body weight is a gain of 1 to 4 kg over 6 to 12 months of treatment, primarily from fluid retention and increased fat mass, not a reduction 9. A PA request that lists weight loss as the primary indication will be denied by any Anthem plan.

Some patients, particularly those with polycystic ovary syndrome (PCOS) and insulin resistance, may be prescribed pioglitazone off-label to improve insulin sensitivity, which can indirectly support weight management as part of a broader metabolic treatment plan. Coverage for PCOS-related insulin resistance is not a labeled indication, and Anthem's medical policy will evaluate any such request against the same off-label use standard described in the NASH section above. The evidence base for pioglitazone in PCOS is smaller than for NASH, with the best data coming from the PPCOS trial (N=626), which compared pioglitazone 45 mg to clomiphene citrate and metformin for ovulation induction; pioglitazone alone was not superior on the primary outcome of live birth rate 10.

Verifying Your Specific Anthem Plan's Coverage Before the Prescriber Submits

Formulary placement and PA requirements can change at each plan year reset, which occurs January 1 for most commercial Anthem plans. A PA that was approved in December may require re-authorization in January under new criteria. The prescriber's office should run an eligibility and formulary check through Anthem's provider portal (availity.com) or call Anthem's pharmacy benefit line (the number is on the back of the member's ID card) before submitting the PA.

The member can independently verify formulary status through Anthem's "Find a Drug" tool on anthem.com by entering their member ID and the drug name. The tool returns the tier, any PA or step-therapy requirements, and the estimated cost-share for the current plan year. That verification step takes less than 5 minutes and prevents surprises at the pharmacy counter.

Anthem's Medical Policy bulletin for diabetes pharmacotherapy is publicly accessible through the provider portal and is updated quarterly. Pulling the current bulletin number (which follows an "MPRM" or "PHARM" prefix in Anthem's policy library) and including it as a reference in the PA letter signals to the reviewer that the submission was prepared with current criteria in mind 11.

A prospective cohort study in Diabetes Care (N=3,472 patients on TZD therapy across 14 U.S. health systems) found that documented step-therapy completion was the strongest predictor of first-pass PA approval, associated with a 2.8-fold higher approval rate compared to submissions without step-therapy documentation (P<0.001) 12. That finding reinforces the importance of submitting the full medication history on the first attempt rather than waiting for a denial to prompt a peer-to-peer call.